GRAIL, Inc.
GRALHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeGRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. The $3.12B market capitalization puts GRAL squarely in mid-cap range for its industry. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer.
Market Cap
$3.12B
Beta
3.22
P/E (TTM)
—
P/E (Fwd)
-7.47
EPS (TTM)
$-10.39
EPS (Fwd)
$-9.72
ROE
-16.1%
ROA
-11.4%
Cash
$823.1M
Total Debt
$51.0M
Free CF
-$107.8M
52W Change
106.4%
Annual Financials
Cash vs Debt
GRAIL, Inc. holds $823.1M in cash against $51.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$107.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -16.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $55.5M (2022) to $147.2M (2025), reflecting a 165% increase over the period.
GRAIL, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, GRAL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GRAIL, Inc.'s trajectory.